Floatz logo

Therapeutic Asset Ratings

181 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cyclophosphamide
Gastroesophageal Junction Adenocarcinoma
Beijing BiotechP3BB (71)
Cyclophosphamide
Urothelial Carcinoma
Beijing BiotechP3BB (71)
Cyclophosphamide
Adenocarcinoma of the Prostate
Beijing BiotechP2BB (70)
Cyclophosphamide
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Beijing BiotechP2BB (70)
Cyclophosphamide
Metastatic Uveal Melanoma
Beijing BiotechP2/3BB (70)
Cyclophosphamide
Recurrent Ovarian Carcinoma
Beijing BiotechP2BB (67)
Cyclophosphamide
Bladder Cancer
Beijing BiotechP3BB (66)
Cyclophosphamide
Fallopian Tube Carcinoma
Beijing BiotechP2BB (66)
Fludarabine
Metastatic Tumor
Beijing BiotechP2BB (65)
Cyclophosphamide
Epithelial Ovarian Cancer
Beijing BiotechP3B (63)
Cyclophosphamide
Neoplasm Metastasis
Beijing BiotechP3B (63)
Cyclophosphamide
Metastatic Colorectal Adenocarcinoma
Beijing BiotechP2B (63)
Cyclophosphamide
Thymic Carcinoma
Beijing BiotechP2B (63)
Fludarabine
Intraocular Melanoma
Beijing BiotechP2B (63)
Fludarabine
Metastatic Pancreatic Ductal Adenocarcinoma
Beijing BiotechP2B (63)
Cyclophosphamide
Metastatic Castration-resistant Prostate Cancer
Beijing BiotechP3B (62)
Fludarabine
Melanoma
Beijing BiotechP2B (62)
Fludarabine
Thymic Carcinoma
Beijing BiotechP2B (62)
Cyclophosphamide
Pancreatic Ductal Adenocarcinoma
Beijing BiotechP2B (61)
Cyclophosphamide
Malignant Pleural Mesotheliomas
Beijing BiotechP2B (60)
Fludarabine
Uveal Melanoma
Beijing BiotechP2B (60)
Fludarabine
Metastatic Cancer
Beijing BiotechP2B (59)
Fludarabine
Primary Peritoneal Cancer
Beijing BiotechP2B (59)
Fludarabine
Metastatic Colorectal Adenocarcinoma
Beijing BiotechP2B (58)
Fludarabine
Epithelial Ovarian Cancer
Beijing BiotechP2B (57)
Showing 1 to 25 of 181 assets
PreviousPage 1 of 8Next